Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Price Target of $15.40 According to Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $18.20.

Several analysts recently issued reports on DRTS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Thursday, October 15th. Piper Sandler upgraded shares of Alpha Tau Medical from a “neutral” rating to an “overweight” rating and upped their target price for the company from $8.00 to $22.00 in a research note on Wednesday. Zacks Research raised shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, November 9th. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Alpha Tau Medical in a report on Tuesday, October 20th.

Alpha Tau Medical Trading Up 0.1%

NASDAQ DRTS opened at $13.38 on Monday. Alpha Tau Medical has a 12 month low of $3.43 and a 12 month high of $15.79. The company has a 50-day moving average of $14.06 and a 200-day moving average of $10.91. The company has a debt-to-equity ratio of 0.15, a current ratio of 11.09 and a quick ratio of 7.79. The company has a market cap of $1.21 billion, a P/E ratio of -12.87 and a beta of 1.28.

Insider Activity

In related news, CFO Raphi Levy sold 2,871 shares of Alpha Tau Medical stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $15.00, for a total transaction of $43,065.00. Following the sale, the chief financial officer directly owned 90,180 shares in the company, valued at $1,352,700. The trade was a 3.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 39.50% of the company’s stock.

Hedge Funds Weigh In On Alpha Tau Medical

Several large investors have recently bought and sold shares of DRTS. Everhart Financial Group Inc. bought a new stake in shares of Alpha Tau Medical during the 2nd quarter worth about $126,000. Renaissance Technologies LLC acquired a new stake in Alpha Tau Medical in the 1st quarter worth approximately $286,000. Finally, Principal Financial Group Inc. acquired a new stake in Alpha Tau Medical in the 1st quarter worth approximately $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.